Hansight Biopharmaceutical Technology

Hansight Biopharmaceutical is a clinical-stage biotechnology company focused on the discovery and development of innovative small molecule therapeutics for oncology. The company specializes in targeting cell cycle regulators and growth factor signaling pathways to address unmet needs in cancer treatment. Its lead programs include selective inhibitors of CDK2 and CDK4/6, as well as FGFR inhibitors, aimed at treating various solid tumors including breast cancer and lung cancer. Hansight leverages its internal R&D capabilities in Shanghai to advance a pipeline of high-potency, low-toxicity drug candidates through clinical development.